西达本胺 T2025

Product Introduction
Bioactivity


英文名: HDAC-IN-7

描述: HDAC-IN-7 (HBI-8000) 是 Chidamide 的一种杂质。Chidamide 是一种可口服的 HDAC 酶 I 类 HDAC1/2/3 和 IIb 类 HDAC10 抑制剂。

细胞实验: Chidamide (CS055) is dissolved in DMSO and stored, and then diluted with appropriate medium before use[2]. Proliferation of the PaTu8988 cells is evaluated using CCK-8 assay. PaTu8988 cells are randomly into 4 groups and incubated in the absence or presence of concentrations of 0, 1.25, 2.5 and 5 μM) of Chidamide for 48 h. Subsequently, 10 μL CCK-8 is added in each well and incubated for 2 h. The optical density of each well is then measured with a microplate reader at 450 nm. The cell survival rate is calculated using the formula: Cell survival rate (%)=1-(ODctrl-ODsample)/ODctrl×100%[2].

激酶实验: HDAC activity is detected as described in the Colorimetric HDAC Activity Assay kit. Each reaction (100 μL) contains nuclear protein (50 μg) extract from leukaemia cells and HDAC substrate. To test the effect of HDACis, Chidamide (CS055) and MS-275 are added to the mixtures and incubated at 37°C for 1 h. The HDAC activities are measured by a microplate readers at 405 nm. The positive control (only nuclear extract and vehicle) is set as 100% and double-distilled water containing 10 μM Trichostatin A, a known strong HDACi, is used as a negative control and set as 0%[2].

体外活性: Chidamide (CS055) at low concentrations dramatically inhibits cell proliferation in each cell line. After Chidamide treatment, cells arrest at the G0/G1 phase in a dose-dependent manner. Western blot analysis indicats that cyclin E1 and E2 protein expression is down-regulated after Chidamide treatment, which is consistent with the cell-cycle analysis. As the changes in cyclin E1 are much more significant than cyclin E2, cyclin E1 is up-regulated in HL60 and K562 cells by lentiviral transduction. The effect on leukaemia proliferation by Chidamide inhibition are largely weakened when cyclin E1 is overexpressed. It is therefore likely that cyclin E1 levels are decreased by Chidamide which induces cell-cycle arrest at the G0/G1 phase[2]. Chidamide causes a significant concentration-dependent inhibitory effect on cell proliferation in comparison to the vehicle-treated cells (P<0.05). The maximal inhibitory effect is reached at 5 μM[3].

体内活性: Inhibition of tumor growth by Chidamide (CS055) treatment is observed in a dose-dependent manner, demonstrating the anti-tumor activity of Chidamide. Control tumors grow to an average volume of 14.51 cm3 after 20 days, and Chidamide-treated tumors grow to 11.68, 11.05 and 8.45 cm3, corresponding to 19.54%, 23.83% and 41.80% growth inhibition respectively. The average tumor mass in animals treated with vehicle is 9.4±2.7 g and is 8.4±2.4 g for animals treated with low-dose Chidamide. In animals treated with a moderate dose of Chidamide, tumor mass is 7.6±1.6 g and those receiving high-dose Chidamide has a tumor mass of 5.4±1.5 g (P<0.01). Additionally, Chidamide treatment prolongs the survival of nude mice bearing HL60 xenografts. Moreover, the level of lipid peroxidation product (MDA), which is a presumptive measure of ROS-mediated injury, is increased in tumor tissue accompanied by treatment of Chidamide, suggesting that Chidamide-induced ROS generation might play a role[2].

存储条件: Powder: -20°C for 3 years | In solvent: -80°C for 1 year

溶解度: DMSO : 41 mg/mL


关键字: HDAC-IN-7 | CS-055 | HDAC IN 7 | HBI 8000 | CS 055 | HBI8000 | HDACIN7

相关产品: CRA-026440 hydrochloride | Sodium 4-phenylbutyrate | Mz325 | 9-hydroxy Stearic Acid | Pyroxamide | Resminostat hydrochloride | JPS016 TFA | HDAC-IN-60 | Gnetol | Scriptaid

相关库: Drug Repurposing Compound Library | HIF-1 Signaling Pathway Compound Library | Anti-Cancer Drug Library | Inhibitor Library | Anti-Cancer Clinical Compound Library | Epigenetics Compound Library | Anti-Cancer Active Compound Library | Anti-Cancer Approved Drug Library | Hematonosis Compound Library | Covalent Inhibitor Library

西达本胺 T2025信息由TargetMol中国为您提供，如您想了解更多关于西达本胺 T2025报价、型号、参数等信息，欢迎来电或留言咨询。

注：该产品未在中华人民共和国食品药品监督管理部门申请医疗器械注册和备案，不可用于临床诊断或治疗等相关用途